Durable reduction in hereditary angioedema (HAE) attack rates with berotralstat over 24 months: results from the phase 3 apeX-2 study

Durable reduction in hereditary angioedema (HAE) attack rates with berotralstat over 24 months: results from the phase 3 apeX-2 study